EFNS guidelines on disease‐specific CSF investigations
Open Access
- 28 April 2009
- journal article
- practice guideline
- Published by Wiley in European Journal of Neurology
- Vol. 16 (6), 760-e163
- https://doi.org/10.1111/j.1468-1331.2009.02595.x
Abstract
We reviewed the literature for disease‐specific markers in cerebrospinal fluid (CSF) and evaluated their diagnostic and prognostic relevance in neurological diseases. High tau protein in combination with low amyloid β levels has a high sensitivity (80%) and specificity (90%) for Alzheimer’s disease (AD) against normal aging and can predict conversion of mild cognitive impairment to AD. The detection of 14‐3‐3 has a high sensitivity (80–90%) and specificity (90%) for the diagnosis of CJD. Low or undetectable CSF hypocretin‐1 (orexin‐1) levels constitute a diagnostic biomarker for narcolepsy with cataplexy. Detection of beta‐2‐transferrin indicates CSF contamination in oto‐ and rhinorrhoe with a sensitivity of >79% at a specificity of 95% similar to the beta‐trace protein (sensitivity >90%, specificity 100%). However, beta‐trace protein is faster and cheaper to perform. Possible future biomarkers are: elevated levels of vascular endothelial growth factor are relatively sensitive (51–100%) and specific (73–100%) for leptomeningeal metastases from solid tumors and are associated with a poor prognosis in this condition. Elevated CSF neurofilament (Nf) levels probably reflect acute neuronal degeneration. The prognostic value of CSF Nf levels is highest in acute conditions such as subarachnoid hemorrhage, acute optic neuritis and neuromyelitis optica.This publication has 108 references indexed in Scilit:
- Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementiasMolecular Psychiatry, 2007
- Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerationsJournal of Neural Transmission, 2007
- 14-3-3 Protein, Total Tau and Phosphorylated Tau in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease and Neurodegenerative Disease in JapanCellular and Molecular Neurobiology, 2006
- Placental growth factor in the cerebrospinal fluid of women with preeclampsiaInternational Journal of Gynecology & Obstetrics, 2005
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosisJournal of Neural Transmission, 2005
- Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptidesElectrophoresis, 2004
- Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsyMovement Disorders, 2002
- Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementiaNeurobiology of Aging, 2002
- β Trace-protein as marker for cerebrospinal fluid fistulaJournal of Molecular Medicine, 1987